Premature Senescence of Vascular Cells Is Induced by HIV Protease Inhibitors
Authors:
- Chloé LefèvReCLChloé LefèvRe
- Martine AuclairMAMartine Auclair
- Franck BoccaraFBFranck Boccara
- Jean-Philippe BastardJBJean-Philippe Bastard
- Jacqueline CapeauJCJacqueline Capeau
- Corinne VigourouxCVCorinne Vigouroux
- Martine Caron-DebarleMCMartine Caron-Debarle
- 1 December 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 30 (12) , 2611-2620
Abstract
Objective— To determine whether and how protease inhibitors (PIs) could affect vascular aging. Methods and Results— HIV therapy with PIs is associated with an increased risk of premature cardiovascular disease. The effect of ritonavir and a combination of lopinavir and ritonavir (for 30 days) on senescence, oxidative stress, and inflammation was evaluated in human coronary artery endothelial cells (HCAECs). These HCAECs were either cotreated or not cotreated with pravastatin or farnesyl transferase inhibitor (FTI)-277 or with 2 antioxidants (manganese [III] tetrakis [4-benzoic acid] porphyrin [MnTBAP] and N-acetyl cysteine). Senescence markers were evaluated in peripheral blood mononuclear cells (PBMCs) from HIV-infected patients under PI treatment. PIs induced senescence markers, prelamin A accumulation, oxidative stress, and inflammation in HCAECs. Senescence markers and prelamin A were also observed in PBMCs from HIV-infected patients under ritonavir-boosted PIs. Pravastatin, FTI-277, and antioxidants improved PI adverse effects in HCAECs. Senescence markers were lower in PBMCs from PI-treated patients cotreated with statins. Conclusion— PIs triggered premature senescence in endothelial cells by a mechanism involving prelamin A accumulation. Accordingly, circulating cells from HIV-infected patients receiving PI therapy expressed senescence markers and prelamin A. Statin was associated with improved senescence in endothelial cells and patient PBMCs. Thus, PIs might promote vascular senescence in HIV-infected patients; and statins might exert beneficial effects in these patients.Keywords
This publication has 46 references indexed in Scilit:
- Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) StudyThe Journal of Infectious Diseases, 2010
- Roles and Mechanisms of Human Immunodeficiency Virus Protease Inhibitor Ritonavir and Other Anti-Human Immunodeficiency Virus Drugs in Endothelial Dysfunction of Porcine Pulmonary Arteries and Human Pulmonary Artery Endothelial CellsThe American Journal of Pathology, 2009
- Aging is associated with greater nuclear NFκB, reduced IκBα, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humansAging Cell, 2008
- A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse modelProceedings of the National Academy of Sciences, 2008
- HIV-protease inhibitors block the enzymatic activity of purified Ste24pBiochemical and Biophysical Research Communications, 2008
- A Potent HIV Protease Inhibitor, Darunavir, Does Not Inhibit ZMPSTE24 or Lead to an Accumulation of Farnesyl-prelamin A in CellsJournal of Biological Chemistry, 2008
- HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cellsProceedings of the National Academy of Sciences, 2007
- Mechanisms of Cardiovascular Disease in Accelerated Aging SyndromesCirculation Research, 2007
- Cardiovascular Risk in Patients with HIV InfectionDrugs, 2006
- HIV protease inhibitor ritonavir increases endothelial monolayer permeabilityBiochemical and Biophysical Research Communications, 2005